Annual EBITDA
-$45.02 M
+$13.32 M+22.83%
December 31, 2023
Summary
- As of February 26, 2025, CSTL annual EBITDA is -$45.02 million, with the most recent change of +$13.32 million (+22.83%) on December 31, 2023.
- During the last 3 years, CSTL annual EBITDA has fallen by -$37.93 million (-534.68%).
- CSTL annual EBITDA is now -538.06% below its all-time high of $10.28 million, reached on December 31, 2019.
Performance
CSTL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$12.02 M
+$520.00 K+4.52%
September 30, 2024
Summary
- As of February 26, 2025, CSTL quarterly EBITDA is $12.02 million, with the most recent change of +$520.00 thousand (+4.52%) on September 30, 2024.
- Over the past year, CSTL quarterly EBITDA has increased by +$11.34 million (+1655.33%).
- CSTL quarterly EBITDA is now at all-time high.
Performance
CSTL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$25.08 M
+$15.72 M+168.01%
September 30, 2024
Summary
- As of February 26, 2025, CSTL TTM EBITDA is $25.08 million, with the most recent change of +$15.72 million (+168.01%) on September 30, 2024.
- Over the past year, CSTL TTM EBITDA has increased by +$70.10 million (+155.70%).
- CSTL TTM EBITDA is now at all-time high.
Performance
CSTL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CSTL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.8% | +1655.3% | +155.7% |
| 3 y3 years | -534.7% | +1655.3% | +155.7% |
| 5 y5 years | -1097.1% | +1655.3% | +155.7% |
CSTL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -23.0% | +22.8% | at high | +145.7% | at high | +132.6% |
| 5 y | 5-year | -538.1% | +22.8% | at high | +145.7% | at high | +132.6% |
| alltime | all time | -538.1% | +22.8% | at high | +145.7% | at high | +132.6% |
Castle Biosciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $12.02 M(+4.5%) | $25.08 M(+168.0%) |
| Jun 2024 | - | $11.50 M(+1229.9%) | $9.36 M(-152.4%) |
| Mar 2024 | - | $865.00 K(+26.3%) | -$17.86 M(-60.3%) |
| Dec 2023 | -$45.02 M(-22.8%) | $685.00 K(-118.5%) | -$45.02 M(-29.0%) |
| Sep 2023 | - | -$3.70 M(-76.5%) | -$63.42 M(-17.7%) |
| Jun 2023 | - | -$15.72 M(-40.2%) | -$77.05 M(+23.7%) |
| Mar 2023 | - | -$26.29 M(+48.4%) | -$62.30 M(+6.8%) |
| Dec 2022 | -$58.34 M(+59.4%) | -$17.72 M(+2.3%) | -$58.34 M(+7.4%) |
| Sep 2022 | - | -$17.32 M(+1680.1%) | -$54.33 M(+13.9%) |
| Jun 2022 | - | -$973.00 K(-95.6%) | -$47.71 M(-13.1%) |
| Mar 2022 | - | -$22.34 M(+63.0%) | -$54.89 M(+50.0%) |
| Dec 2021 | -$36.60 M | -$13.70 M(+28.0%) | -$36.60 M(+34.8%) |
| Sep 2021 | - | -$10.70 M(+31.3%) | -$27.15 M(+34.3%) |
| Jun 2021 | - | -$8.15 M(+101.4%) | -$20.21 M(+60.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$4.05 M(-4.8%) | -$12.57 M(+77.1%) |
| Dec 2020 | -$7.09 M(-169.0%) | -$4.25 M(+12.9%) | -$7.09 M(-4861.1%) |
| Sep 2020 | - | -$3.76 M(+645.3%) | $149.00 K(-98.6%) |
| Jun 2020 | - | -$505.00 K(-135.4%) | $10.94 M(-8.5%) |
| Mar 2020 | - | $1.43 M(-52.4%) | $11.96 M(+16.3%) |
| Dec 2019 | $10.28 M(-373.3%) | $2.99 M(-57.4%) | $10.28 M(-13.6%) |
| Sep 2019 | - | $7.03 M(+1275.3%) | $11.89 M(+475.6%) |
| Jun 2019 | - | $511.00 K(-301.2%) | $2.07 M(-307.7%) |
| Mar 2019 | - | -$254.00 K(-105.5%) | -$994.60 K(-73.6%) |
| Dec 2018 | -$3.76 M(-63.8%) | $4.61 M(-264.7%) | -$3.76 M(-55.1%) |
| Sep 2018 | - | -$2.80 M(+9.7%) | -$8.37 M(+50.2%) |
| Jun 2018 | - | -$2.55 M(-15.6%) | -$5.57 M(+84.4%) |
| Mar 2018 | - | -$3.02 M | -$3.02 M |
| Dec 2017 | -$10.40 M | - | - |
FAQ
- What is Castle Biosciences annual EBITDA?
- What is the all time high annual EBITDA for Castle Biosciences?
- What is Castle Biosciences annual EBITDA year-on-year change?
- What is Castle Biosciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for Castle Biosciences?
- What is Castle Biosciences quarterly EBITDA year-on-year change?
- What is Castle Biosciences TTM EBITDA?
- What is the all time high TTM EBITDA for Castle Biosciences?
- What is Castle Biosciences TTM EBITDA year-on-year change?
What is Castle Biosciences annual EBITDA?
The current annual EBITDA of CSTL is -$45.02 M
What is the all time high annual EBITDA for Castle Biosciences?
Castle Biosciences all-time high annual EBITDA is $10.28 M
What is Castle Biosciences annual EBITDA year-on-year change?
Over the past year, CSTL annual EBITDA has changed by +$13.32 M (+22.83%)
What is Castle Biosciences quarterly EBITDA?
The current quarterly EBITDA of CSTL is $12.02 M
What is the all time high quarterly EBITDA for Castle Biosciences?
Castle Biosciences all-time high quarterly EBITDA is $12.02 M
What is Castle Biosciences quarterly EBITDA year-on-year change?
Over the past year, CSTL quarterly EBITDA has changed by +$11.34 M (+1655.33%)
What is Castle Biosciences TTM EBITDA?
The current TTM EBITDA of CSTL is $25.08 M
What is the all time high TTM EBITDA for Castle Biosciences?
Castle Biosciences all-time high TTM EBITDA is $25.08 M
What is Castle Biosciences TTM EBITDA year-on-year change?
Over the past year, CSTL TTM EBITDA has changed by +$70.10 M (+155.70%)